• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Huntington’s disease Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Huntington’s disease.
  • The report assesses Huntington’s disease pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Huntington’s disease pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Huntington’s disease ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

Eli Lilly, Scios, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Ceregene, Genzyme Corporation, Cogent Neuroscience [CEASED], Ipsen, Vertex Pharmaceuticals, NeuroSearch Sweden AB, ReNeuron, Tapestry Pharmaceuticals, Prana Biotechnology, TopoTarget, NeuroNova AB, Almirall-Prodesfarma; Neurocrine Biosciences, Sirtris Pharmaceuticals, Medivation, irna Therapeutics, Targeted Genetics, SYGNIS Bioscience GmbH

Key Drugs:

Remacemide, LY 274614, NPC 12626, OPC 14117, Dapiclermin, CERE 120, ZVAD fmk, Porcine neural cell product-HD, Tetrathiomolybdate, AM 404, BN 82451, VX 563, Pridopidine, HD 1 – Tapestry Pharmaceuticals, PBT 2, Latrepirdine

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel